Abstract: Aspects of the disclosure relate to compositions and methods for delivering inhibitory nucleic acids to prokaryotic cells using extracellular vesicles (e.g., exosomes, microvesicles, etc.) derived from mammalian cells. The disclosure provides methods for regulating the expression of one or more genes in a prokaryotic cell. The disclosure further provides methods of treating diseases associated with prokaryotic gene dysregulation.

Abstract: Described are small molecule embodiments, ALS compounds, that bind with the (G4C2)exp RNA repeat transcription of the chromosome 9 open reading frame 72 involved in amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD). These ALS compounds comprise a pyridocarbazole moiety having at least one substituent. Preferred ALS compounds comprise bridged dimers of the pyridocarbazole moiety in which the bridge between the two pyridocarbazole moieties is a polyoxyethylenyl group or an aminobispolyoxyethylenyl group.

Abstract: Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic segments, including those encoding therapeutic polypetides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV-based gene therapeutic regimen for treating and/or ameliorating autoimmune disorders such as multiple sclerosis.

Abstract: The present disclosure describes systems and methods for hardware-assisted malware detection. One such system comprises a memory; and a hardware processor of a computing device operatively coupled to the memory. The hardware processor is configured to execute a software application suspected of being malware; monitor behavior of the software application at run-time; and acquire an input time sequence of data records based on a trace analysis of the software application, wherein the input time sequence comprises a plurality of features of the software application. The hardware processor is further configured to classify the software application as being a malicious software application based on the plurality of features of the software application; and output a ranking of a subset plurality of features by their respective contributions towards the classification of the software application as being malicious software.

Abstract: Embodiments of the present disclosure provide for coaxial nozzles, capsule fabrication systems comprising coaxial nozzles, and methods of capsule fabrication using capsule fabrication systems. In certain embodiments, coaxial nozzle configurations, capsule fabrication systems, and methods as described herein can be used for multi-layered capsule fabrication.

Abstract: In one aspect, the present disclosure relates to a contact lens comprising a disclosed lubricious surface layer. In a further aspect, the lubricious surface layer comprises a polyacrylamide, e.g., a poly(N,N-dimethylacrylamide. In various aspects, the lubricious surface layer is formed at the surface of a contact lens. In a further aspect, the lens can be a hydrogel lens. In a further aspect, the lens can be a silicone hydrogel lens. The present disclosure also pertains to methods of forming the disclosed lubricious surface layers on a surface of a contact lens. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Provided herein are immunotherapy compositions for treating a subject with a glioblastoma, comprising a peptide formulation derived from at least one cancer or stemness factor, nanoparticles containing peptides derived from at least one cancer or stemness factor, dendritic cells containing peptides derived from at least one cancer or stemness factors, RNA coding at least one cancer or stemness factor, nanoparticles containing RNA coding at least one cancer or stemness factor, dendritic cells containing RNA coding at least one cancer factor or stemness factor, or an inhibitor of at least one cancer or stemness factor. Also provided are methods of inhibiting a glioblastoma stem-like cell (GSC), methods of treating a subject for glioblastoma, and methods of reprogramming an astrocyte to a glioblastoma stem-like cell (GSC) using such immunotherapy compositions.

Abstract: In general, the disclosure relates to methods and compositions for preparing colorants useful for preparing pigmented hydrogels. The disclosure further relates to pigmented hydrogels comprising the disclosed colorants. In some instances, the colorant is an alcohol extract of an agro-material, such as turmeric, paprika, spinach, and/or pokorny woad or the colorants comprise one or more of: a carotenoid, chlorophyll-a, chlorophyll-b, a curcumoid, or indigorubin. Alternatively, the colorant can be carbon black. The disclosure further relates to contact lenses comprising the disclosed pigmented hydrogels.

Abstract: Provided herein are charge complementary peptides coupled to a cargo polypeptide (e.g., a uricase protein) (e.g., uricase) that are capable of self-assembling under stimulating conditions. The charge complementary peptides can be capable of forming supramolecular structures. Also provided herein are methods of using the charge complementary peptides provided herein (e.g., to treat gout).

Abstract: The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depression, pain, drug addiction, drug use, and/or drug seeking behavior. Also provided are compositions, medicaments, and methods including such compounds.

Abstract: Described herein are eye implants that can include a pressure-responsive material that can be capable of changing color in response to pressure exerted on it. Also described here are methods of implanting and using the eye implants described herein to monitor intraocular pressure in a subject. The pressure-responsive material can be used to diagnose and monitor human or animal subjects.

Abstract: Aspects of the disclosure relate to compositions and methods for treating certain (e.g., CD33-positive) cancers. In some aspects, the disclosure provides antibodies that specifically bind to CD33 protein variants that lack an IgV domain. In some aspects, the disclosure provides adaptable cell engagers (ACEs) and recombinant proteins (e.g., BiTEs) comprising an anti-CD33 antibody of the disclosure and an anti-CD3 antibody. In some embodiments, the disclosure provides methods of treating cancer by administering the antibodies, ACEs, or recombinant proteins (e.g., BiTEs) to a subject in need thereof.

Abstract: The disclosure provides a method of preparing a functionalized cyclic polymer the method including reacting a metal-alkylidyne compound, metallacycloalkylene compound, or metallacyclopentadiene compound with a plurality of alkynes to form the functionalized cyclic polymer, wherein at least one alkyne comprises a functional group capable of further reacting to form a modified polymer. Also provided is a stereoregular functionalized cyclic polymer prepared by the method of the disclosure.

Abstract: Provided is an oxidizing composition, in which a liquid medium is substantially inert in the presence of an oxidizing electrophile contained in the liquid medium. The composition comprises (a) an oxidizing electrophile comprising a main group element in oxidized form and at least one conjugate anion of an oxygen acid; (b) a non-oxidizable liquid selected from a fluorinated hydrocarbon, a sulfone, a deactivated arene, a deactivated aliphatic, a deactivated heteroarene, a deactivated heteroaliphatic, and a combination thereof; and (c) optionally one or more salt additives. Further provided are a method of using the oxidizing composition to oxidize a substrate and a method of generating and/or regenerating an oxidizing electrophile comprising a main group element.

Abstract: Macrocyclic polyalkene homopolymers and copolymers can be formed and converted to macrocyclic polyalkanes or macrocyclic poly(alkane-co-alkene) upon hydrogenation or, when the macrocyclic polyalkene is reacted with an alkene in the presence of an olefin metathesis catalyst, to a macrocyclic poly(alkane-co-alkene) comprising vicinal —C(?CR2)—'s. Upon hydrogenation of a macrocyclic poly(alkane-co-alkene) comprising vicinal —C(?CR2)-'s, macrocyclic poly(alkane)s or poly(alkane-co-alkene)s with isolated —C(?CR2)- groups can be provided, depending on the degree of hydrogenation. The poly(alkane-co-alkene)s with isolated —C(?CR2)- units can be used to form poly(macrocyclic poly(alkane-co-alkene))s, poly(macrocyclic poly(alkane))s, and/or bi-, tri-, and/or multi-macrocyclic poly(alkane-co-alkene)s or bi-, tri-, and/or multi-macrocyclic poly(alkane)s.

Abstract: Provided herein are methods and compositions for treating an eye disorder, for example cone-rod dystrophy type 6 (CORD6). In certain aspects, a therapeutically effective amount of a composition comprising nucleic acids is administered to a subject to treat an autosomal dominant disorder or condition, such as a condition associated with a dominant mutation in a guanylate cyclase 2D (GUCY2D) gene, such as knocking out a dominant mutant form of the gene in the subject. Further provided herein are recombinant AAV particles that comprise one or more recombinant AAV genomes comprising nucleic acids that encode a guide RNA that targets a GUCY2D gene and/or an RNA-guided endonuclease.

Abstract: Provided herein is a method, apparatus, and system for detecting conditions indicative of an attempt to attach a skimming device to a payment device. Methods may include monitoring at least one wire among a plurality of wires between a card reader device and a motherboard; determining voltage consumption; determining current consumption; identifying a change in voltage consumption or current consumption satisfying a predetermined value; and providing for transmission of an alert of a condition indicating possible attachment of a card skimming device. Methods may include generating a status message periodically and transmitting the status message to a remote entity. The change in voltage consumption or current consumption satisfying the predetermined value may include a voltage instability exceeding a predetermined range about an anticipated voltage. The change in voltage consumption or current consumption satisfying the predetermined value may include a decrease in current satisfying the predetermined value.

Abstract: An exemplary focused tomography system comprises an x-ray transmitter that is configured to emit a radiation beam and an x-ray detector that is configured to detect incident radiation from the radiation beam. The system further includes an adaptive collimator device arranged between the x-ray transmitter and the x-ray detector and a controller device connected to the x-ray transmitter that is configured to cause the x-ray transmitter to emit the radiation beam at a first radiation dosage level when a path of the radiation beam intersects a region of interest of the subject and cause the x-ray transmitter to emit the radiation beam at a second radiation dosage level when the path of the radiation beam does not intersect the region of interest of the subject, such that the second radiation dosage level is less than the first radiation dosage level. Data within the region of interest can be reconstructed with image quality equivalent to traditional computed tomography scans.

Abstract: The invention is directed towards compounds (e.g., Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof).

Abstract: Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these capsid variants are capable of evading neutralization by the host humoral immune response. The recombinant AAV3B variant proteins and viral particles disclosed herein were identified from a variant AAV3B capsid library that was engineered by making substitutions in only the variable regions of the capsid. Some embodiments of the AAV3B capsid variants disclosed herein comprise the AAV3B-DE5 variant, which contains 24 mutations relative to wild-type. Compositions of these variant AAV particles are provided that are useful for transducing and delivering therapeutic transgenes to cells, such as liver cells, and thus treat diseases and disorders pertaining to these cells.